TABLE 1.
MIC50 for vancomycin and gentamicin alone and in combination with tranexamic acid (TXA) using the standard visualization method.
| Treatment |
Staphylococcus aureus MIC50 (ranges) mg/L |
MIC50 fold reductions (no.) |
Staphylococcus epidermidis MIC50 (ranges) mg/L |
MIC50 fold reductions (no.) | Overall MIC50 (ranges) mg/L |
MIC50 fold reductions (no.) |
| Vancomycin | 0.12 (0.12–0.25) | 0.25 (0.12–0.5) | 0.25 (0.12–0.5) | |||
| Vancomycin + TXA 10 mg/ml | 0.12 (0.12–0.25) | 0 | 0.12 (0.03–0.25) | 1 | 0.12 (0.03–0.25) | 1 |
| Vancomycin + TXA 50 mg/ml | 0.25 (0.12–0.25) | NA* | 0.25 (0.03–0.5) | 0 | 0.25 (0.03–0.5) | 0 |
| Gentamicin | 4 (0.25–16) | 16 (0.5–32) | 8 (0.25–32) | |||
| Gentamicin + TXA 10 mg/ml | 0.12 (0.06–0.25) | 5 | 1 (0.06–2) | 4 | 0.5 (0.06–2) | 4 |
| Gentamicin + TXA 50 mg/ml | 0.12 (0.06–0.5) | 5 | 0.25 (0.06–0.5) | 6 | 0.12 (0.06–0.5) | 6 |
TXA, tranexamic acid; MIC, minimal inhibitory concentration; NA, not applicable. *1-fold increase was observed.